MedMira Announces 2nd Caribbean Distributor Receives Initial Order for Rapid HIV & Rapid HCV Tests HALIFAX, Feb. 10 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow-through diagnostic technology, today announced it has signed a distribution agreement with ExporTrade Corporation of Boca Raton, Florida, who will represent MedMira in selected countries in the Caribbean, South and Central America, bringing to two the number of active distributors in the region. With the signing of the agreement, MedMira received an initial order for MiraWell(TM) HIV and MiraWell(TM) HCV rapid tests. "Securing a second distributor in the Caribbean region will provide us with broader market coverage in one of the most severely HIV-affected regions in the world. In addition to its long and successful history in this region, the strength of ExporTrade's government relationships was very attractive to us," says Giles Crouch, MedMira's vice president of marketing and business development. He continues, "We are confident that taking our proven technology into ExporTrade's solid distribution network will be extremely valuable in expanding our market share in this region." Says Jeff Firestone, president of ExporTrade, "In our search for a company that could provide a reliable, established rapid testing product line in combination with the technical and marketing support necessary to bring this critical test to market, MedMira was clearly our number one choice." ExporTrade has been operating successfully in the Caribbean for over twenty- five years and has well-established relationships with island healthcare facilities and governments. Mr. Firestone continues, "We have found MedMira to be a company with a social conscience and together, our similar vision will help to eradicate this deadly disease in this area". In the South and Central American and Caribbean regions, (population of 440 million), the estimated infection rate has climbed from 0.6% in the mid 1990's to over 2.6% in 2004. This represents the largest HIV-infected population outside of Africa. UNAIDS expects the pandemic to increase in coming years without effective diagnosis and treatment programs. Over 50% of HIV-infections are in women and nearly 20% are children, casting serious economic concerns for the future of the labor force in this region of the world. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com/. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. DATASOURCE: MedMira Inc. CONTACT: Media Contact: Please Contact: Investor Relations, Dr. James Smith: (902) 450-1588 or e-mail:

Copyright